Onkologie. 2021:15(1):40-42 | DOI: 10.36290/xon.2021.008
Even a patient with BRAF-mutated malignant melanoma has a chance for long-term survival
- Onkologické oddělení, Krajská nemocnice Tomáše Bati, a. s., Zlín
Malignant melanoma is an aggressive tumour with a rising incidence and an incidence shift to younger age categories. In the presence of metastases, it has for years been associated with a very rapid, dismal prognosis (1). Not even oncological therapeutic procedures (chemotherapy) could prolong the median survival by more than 6-9 months. The discovery of the BRAF V600 mutation in 2002 was a breakthrough in the understanding of the aetiology of malignant melanoma. In the case of skin melanoma, a BRAF mutation is detected in 40-60 % of all cases, portending a worse prognosis for the patient (2).
Keywords: checkpoint inhibitors, vemurafenib, metastatic malignant melanoma, BRAF mutation.
Published: March 1, 2021 Show citation
References
- Dusek L, Muzik J, Kubasek M, et al. Epidemiology of malignant tumors in the Czech Republic (online). Masaryk University, Brno (Czech republic) 2005. Dostupné na http://www.svod.cz/?sec=analyzy.
- Lemech CH, Inflante J, Arkenau HT. The potencial for BRAf V600 inhibitors in advanced cutaneous melanoma: rationale and lates evidence. Nature 2010; 467: 596-599.
- Chapman PB, Hauschild A, Robert C, et al. Improved survival wih vemurafnib in melanoma with BRAF V600 mutation. New Engl J Med 2011; 364: 2507-2516.
Go to original source... 
Go to PubMed... - Krajsová I. Dlouhodobé přežití při monoterapii vemurafnibem. In: Remedia (online). (cit. 1/2017). Dostupné z http.//remedia.cz/Clanky/Kazuistiky/Dlouhodobe-preziti-pri - monoterapii-vemurafenibem/6-ah-2f5.magarticle.aspx.